

**I- PERSONAL INFORMATION:**

- Name: Ahmed El Saied El Bastawisy.
- Birth Date: 13-3-1978.
- Marital status: Married.
- Military service: Completed.
- Address:-Home: Villa 117/2 C, The Lakeview compound, 5th Settlement, Cairo, Egypt.

-Private Center: Platinum Oncology Center
-308-309 Sway mall, Mohamed Naguib Axis, 5th settlement, Cairo Egypt

- Telephone: Home: +20228123379.
Mobile: +2 0100-1104774.
Private center:
+201016757975
+201018693883
- Email: a_s_basta@hotmail.com.
ahmed.elbastawisy@nci.cu.edu.eg
Platinumoncologycare@gmail.com
- website: www.platinumoncologycare.com

II- EDUCATIONAL BACKGROUND:

- M.B.B.Ch Kasr EL Aini Faculty of Medicine, Cairo University, Oct. 2001, Degree: Excellent with honours.
- M.Sc. in Internal Medicine, Kasr EL Aini Faculty of Medicine, Cairo University, June 2006, Degree: Very good.
- Doctorate degree, MD of medical oncology and Haematology, NCI, Cairo University, May 2010.
- European certification in medical oncology: passed ESMO examination, Berlin, Germany, September, 2009.
- European recertification by ESMO-MORA (Medical Oncology Recertification Approval) on November 2014. (Valid from 2014-2019).
- European recertification by ESMO-MORA (Medical Oncology Recertification Approval) on December 2019. (Valid from 2019-2024)
- European recertification by ESMO-MORA (Medical Oncology Recertification Approval) on January 2025. (Valid from 2025 to 2030).

III-CURRENT EMPLOYMENT STATUS

- Professor of Medical Oncology, Haematological malignancies, National Cancer Institute (NCI), Cairo University.
- Chairman of OncoSpecialized Foundation.
- Founder and Chairman of <<Platinum Oncology Care>> (ESMO Designated Center for 3 consecutive times since 2019 valid till 2028)

IV- PROFESSIONAL EXPERIENCE

- Resident of Medical Oncology and Haematology, National Cancer Institute, Cairo University, from July 2003 to July 2006 and then was advocated as demonstrator of medical oncology at the same university.
- Military service as resident of Hematology, Oncology and bone marrow transplantation Maadi Armed Forces Hospital from December 2003 to December 2004.
- Resident of Internal Medicine at Kasr EL Aini University hospitals from March 2005 to June 2005.

- Intern at Kasr El Aini Hospital from March 2002 to March 2003.
- Assistant lecturer of medical oncology and haematology, NCI, Cairo University from July 2007 till May, 2010.
- Part time specialist of oncology at health insurance hospitals, Cairo since June 2006 till April 2010.
- Part time specialist of oncology, haematology and BMT at International Medical Centre (IMC) military forces, Egypt since April 2007 till October 2009.
- Lecturer and consultant of medical oncology, Haematological malignancies at NCI, Cairo University from July 2010 till July 2015.
- First Consultatnt of Medical Oncology, Baheya Cancer Hospital from 11/January 2015 till 20 Septemebr 2025.
- Associate Professor of Medical Oncology, Haematological malignancies at NCI, Cairo University from July 2015.
- Director of Research Center , NCI, Cairo University.10th May, 2020 till 20 July 2022.
- Professor of Medical Oncology, Haematological malignancies, NCI, Cairo University.July, 2020.
- Member of reviewers committee of Supreme Council of Universitis for promotion of oncology professors.

V- TEACHING EXPERIENCE:

Teaching of candidates of Masters, Medical doctorate and Fellowships degrees of Medical, Radiation and Surgical Oncology. NCI, Cairo University from 2010 till now.

VI- ORGANIZATIONAL/MANAGERIAL EXPERIENCE:

-Supervisor of training program of residents, assistant lecturers, candidates of Masters and Medical Doctorate degrees, NCI, Cairo University. From 2015 till April 2020.

- Director of Research Center , NCI, Cairo University. from 10th May, 2020 till 20 July 2022.

Other activities:

General Courses:

- Addiction management course, arranged by Presidency of the Council of Ministers, April 2002.
- Research methodology and statistics course at Medical Education Development Centre, Cairo University. Dec. 2004.
- Fluent English language (passed TOEFL exam, score 613, on March 2005 and May 2010)
- Excellent computer skills: holding general diploma of computer sciences from Language & Computer Sciences Experts (LCSE), Cairo. May 2006.
- Research methodology and statistics course at Medical Education Development Centre, Cairo University, Dec. 2004.
- International conference on Harmonization / Good Clinical Practice ICH/GCP workshop, by Maureen Stannard, Consultant clinical research affairs, UK, November 2007.
- Palliative Integrated Oncology Advanced EPEC-Oncology Course from: The Institute for Palliative Medicine at San Diego Hospice. April 2009.
- Training course in IHC-GCP and Human subject protection at National Training Institute, Egypt, and July 2009.
- GCP Course by University of Hong Kong, Dubai, 12-15 September 2014.
- Training course in: Use of technology in teaching at Faculty and Leadership Development Center (FLDC), Cairo University 2010.

- Training course in: Effective Presentation at FLDC, 2010.
- Training course in: New Trends in Teaching at FLDC, 2010.
- Training course in Financial and Law Aspects in FLDC, 2010.
- Training course in Competitive Research Projects at FLDC, 2010.
- Training course in Scientific Publishing at FLDC, 2010.
- Training course in: Exams and Students Evaluation Systems at FLDC, December 2014.
- Training course in: Effective Teaching Skills at FLDC, December 2014.
- Training course in: Research Ethics at FLDC, December 2014.
- Training course in: Managing Research teams at FLDC, February 2015.
- Training course in: Conference Organization at FLDC, February 2015.
- Training course in: Creative Thinking, FLDC. February 2015.
- Training course in: Conference Organization at FLDC, February 2015.
- Training course in: Conference Organization at FLDC, February 2015.
- Training course in: Total Quality Management in Healthcare at FLDC, January 2020.
- Training course in: Statistical Analysis of Bio-Experiments at FLDC, January 2020.
- Training course in: Managing Time and Meetings at FLDC, January 2020.

-
- Training course in: Communication Skills at FLDC, January 2020.
 - Training course in: Egyptian Knowledge Bank (EKB) and Searching for Sources at FLDC, January 2020.
 - Training course in: Critical Thinking at FLDC, February 2020.
 - Training course in: Change Management at FLDC, August 2020.
 - Training course in: Strategic planning at FLDC, August 2020.
 - Training course in: Stress Management at FLDC, August 2020.
 - Training course in: University Code of ethics at FLDC, August 2020.

RESEARCH EXPERIENCE:**Editorial Board Member:**

- **Journal of case reports in Oncology and Therapy**
- **Cancer therapy & Oncology International Journal (CTOIJ)**

- **Reviewer:**

- **Oncology Letters**
- **Oncology reports**
- Journal of Cancer Therapy**
- British Journal of Pharmaceutical Research**
- International Journal of Medical and Pharmaceutical Case reports**
- Journal of Advances in Medical and Pharmaceutical sciences**
- British Journal of Medicine and Medical Research**
- Journal of Cancer and Tumor International**
- ecancermedicalseience**
- **Frontiers in Oncology and Frontiers in Surgery: Review Editor**
- **Biomedicines**

Publications:

- Inflammatory breast cancer in Egypt: is it really a separate entity? A.E.El Bastawisy et al. Annals of oncology, volume 21, supplement 8, viii 116, Oct.2010.
- Inflammatory breast cancer: is it really a separate entity?:AS Bastawisy, RM Gaafar, SS Eisa, GM Amira, and MH Helal.ecancer 2012, 6:250 DOI: 10.3332/ecancer.2012.250.
- Aberrant expression of cell cycle regulatory genes predicts overall and disease free survival in malignant pleural mesothelioma patients.Abeer A. Bahnassy, Abdel-Rahman N. Zekri, Amany A. Abou-

Bakr, Mervat M. El-Deftar, Ahmad El-Bastawisy, Mona A. Sakr a, Ghada M. El-sherif, Rabab M. Gaafar: Experimental and Molecular Pathology 93 (2012) 154–161.

- Diagnostic and prognostic issues in inflammatory breast cancer. THE BREAST: volume 22 supplement 1 March 2013 ISSN 0960 9776, poster 275)
- Plasma CA 19-9 in Advanced Non-Small Cell Lung Cancer, Ahmed Abdallah, Mohamed Belal, Ahmed El Bastawisy, & Rabab Gaafar, Cancer and Clinical Oncology; Vol. 2, No. 2; 2013.
- UGT1A1*28 polymorphism and Vomiting in advanced colorectal cancer, Ahmed El Bastawisy, Amany El-Zeiny, Samar Farid , Abeer Bahnasy, Annals of Oncology, volume 24 supp 4, iv93.2013.
- UGT1A1*28 polymorphism in advanced colorectal cancer: The story is not yet ended. Ahmed El Saied El Bastawisy, Amany El-Zeiny, Samar Farid, Abeer Bahnasy; J Clin Oncol 32, 2014 (suppl 3; abstr 516)
- Mistletoe preparation (Viscum Fraxini²) as palliative treatment of malignant pleural effusion, R. Gaafar, F.A. Kassem, A.E. Bastawisy, Support Care Cancer (2013) 21 (Suppl 1):S1–S301.
- UGT1A1*28 polymorphism and vomiting in advanced colorectal cancer. Ahmed El Saied El Bastawisy, Amany El-Zeiny, Samar Farid, Abeer Bahnasy; J Clin Oncol 31, 2013 (suppl; abstr e14678).
- Prognostic value of neutrophil lymphocyte ratio in second line advanced malignant pleural mesothelioma: Ahmed El Bastawisy, Maha Yahia,

Rabab Gaafar
: Journal of Thoracic Oncology, Volume 8,
Supplement 2, November 2013.S1096.

- Palliation of Malignant Pleural Effusion by Pleurodesis a comparative study : AbdelRahman M. Abdelrahman, Fatma Aboulkasem, Rabab Gaafar, Ahmed El Bastawisy, Maha Yahia, Hala Aziz: Journal of Thoracic Oncology, Volume 8, Supplement 2, November 2013, S717.
- Plasma Vascular endothelial growth factor 165 (VEGF 165) in advanced Non-small cell lung cancer. Ahmed Abdallah, Mohamed Belal, Ahmed El Bastawisy, Rabab Gaafar: Journal of Thoracic Oncology, Volume 8, Supplement 2, November 2013, S802.
- A. Bastawisy, A. Bahnasy, A. El-Zeiny and S. Farid, "UGT1A1*28 Polymorphism in Advanced Colorectal Cancer: The Story Is Not Yet Ended," Journal of Cancer Therapy, Vol. 5 No. 1, 2014, pp. 53-59. doi: 10.4236/jct.2014.51007.
- El Bastawisy Ahmed, El azzouny Mahmoud, Mohammed Gamal, Awad allah Ahmed and Behiry Eman (2014) Serum cytokeratin 19 fragment in advanced lung cancer: could we eventually have a serum tumor marker? ecancer 8 394.
- El Bastawisy, A. , El Azzouny, M. , Mohamed, G. , Allah, A. and Behiry, E. (2014) Diagnostic and

Prognostic Value of Serum Tissue Polypeptide Antigen in Advanced Lung Cancer. *Journal of Cancer Therapy*, 5, 231-237. doi: 10.4236/jct.2014.53030.

- Abdallah, A., Belal, M., El Bastawisy, A., & Gaafar, R. (2014). Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. *Oncology Letters*, 7(6), 2121-2129.
- Gaafar Rabab, Abdel Rahman Abdel Rahman M, Aboukasem Fatma and El Bastawisy Ahmed (2014) Mistletoe preparation (*Viscum Fraxini-2*) as palliative treatment of malignant pleural effusion: a feasibility study with comparison to bleomycin *ecancer* 8 424
- A. El Bastawisy, H.R. Nassar, N. Elhady, and A. Bahnasy 33P STEM CELL LIKE PHENOTYPE IN INFLAMMATORY BREAST CANCER *Ann Oncol* (2014) 25 (suppl 1): i12 doi:10.1093/annonc/mdu066.14
- Ahmed E. El Bastawisy, Abeer A. Bahnasy, Neveen M. Elhady, and Hanan R. Nassar O1-11-4 SOX2 IN INFLAMMATORY BREAST CANCER: DID WE EVENTUALLY HAVE AN ANSWER? *Ann Oncol* (2014) 25 (suppl 5): v48 doi:10.1093/annonc/mdu435.21
- Zineb Benbrahim, Ahmed S. El Bastawisy, Soumaya Labidi, Adil Najdi, Chakib Nejjari, Hammouda Boussen, and Nawfel Mellas O1-11-1 PROGNOSTIC POWER OF MOLECULAR SUBTYPES IN INFLAMMATORY BREAST CANCER: A MULTICENTRIC

STUDY *Ann Oncol* (2014) 25 (suppl 5): v48
doi:10.1093/annonc/mdu435.20

- El Bastawisy, A., Yahia, M., Rahman, A. and Gaafar, R. (2014) Prognostic Value of Neutrophil Lymphocyte Ratio in Second Line Advanced Malignant Pleural Mesothelioma. *Journal of Cancer Therapy*, 5, 717-722. doi: 10.4236/jct.2014.57080.
- Bahnassy AA, Zekri A-RN, El-Bastawisy A, et al. Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease. *World Journal of Gastroenterology* : WJG 2014;20(48):18240- doi:10.3748/wjg.v20.i48.18240.
- El-Zeiny A, El-Bastawisy A et al., UGT1A1*28 Polymorphism Related Toxicities are more Frequent in Chemotherapy Naïve Patients. *American Journal of PharmTech Research* 2015.
- Bahhnassy, A., Mohanad, M., Shaarawy, S., Ismail, M. F., El-Bastawisy, A., Ashmawy, A. M., & Zekri, A. R. (2015). Transforming growth factor- β , insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer. *Molecular medicine reports*,12(1), 851–864. doi:10.3892/mmr.2015.3560
- Bahnassy A, Mohanad M, Ismail MF, Shaarawy S, El-Bastawisy A, Zekri AN. Molecular biomarkers for prediction of response to treatment and survival in

triple negative breast cancer patients from Egypt. *Exp Mol Pathol.* 2015 Jul 30; 99(2):303-311. doi: 10.1016/j.yexmp.2015.07.014. [Epub ahead of print]. PMID: 26232605.

- Abdel-Rahamn Zekri, Abeer A Bahnassy, Ahmed El Bastawisy et al. Prognostic and predictive values of CD68+ macrophage and aberrant expression of cathepsin L, IL-12, CTL4A genes in classic Hodgkin's lymphoma. *Cancer Research* 75(15 Supplement):2217-2217 · August 2015 DOI: 10.1158/1538-7445.AM2015-2217
- Impact of histological subtypes on clinical outcome of thymoma : Ahmed El Bastawisy, Maha Yahia, Mohamed Rahouma, Omina Abo Elazm, Mai Gad, Jaylan Ahmed: *Journal of Thoracic Oncology* 10 (number 9, Supplement 2) : S755. Sep 2015.
- Ezzeldin, N., El-Lebedy, D., Darwish, A., El-Bastawissy, A., & Shalaby, A. E. (2015). Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer. *Contemporary oncology (Poznan, Poland)*, 19(6), 441–445. doi:10.5114/wo.2015.56202
- P2.03b-054 Biomarker Predictors in NSCLC Yahia, Maha et al. *Journal of Thoracic Oncology*, Volume 12, Issue 1, S968 - S969
- Ismail M, Bastawisy AE, Gaafar R, Bahnassy A, Allahloubi N. Molecular markers in advanced non

small cell lung cancer patients receiving gemcitabine & cisplatin, J Thorac Oncol. 2016 Apr;11(4 Suppl):S128. doi: 10.1016/S1556-0864(16)30272-6. Epub 2016 Apr 15. PMID: 27198299

- Ahmed El Bastawisy, A Hilal, Z Samir, Y Kamal. Clinical differences between right and left colonic cancer. Annals of Oncology 27(suppl 2):ii88.1-ii88 · June 2016 DOI: 10.1093/annonc/mdw201.09
- Sinha, A., Paul, B., Sullivan, L., Sims, H., Bastawisy, A., Yousef, H., Zekri, A., Bahnassy, A., & ElShaym, W. (2016). BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions. Oncotarget, 5. Retrieved from <http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path%5B%5D=14357>
- Abeer A. Bahnassy, Eman Abdelzaher,, Rania Gaber, Gamal Elhosseiny, Awad Abdel Moniem A. Rafalla4, Abdel-rahman N. Zekri, Ahmad El-Bastawisi, Hend F. Yousif1 and Layla Kamal Younis. RUNX2 and WWOX genes as molecular biomarkers and candidates for targeted therapy in Egyptian patients with primary conventional osteosarcoma. Applied Cancer Research201636:4 DOI: 10.1186/s41241-016-0001-9

- Ezzeldin, N., El-Lebedy, D., Darwish, A., El-Bastawisy, A., Hassan, M., Abd El-Aziz, S., ... Saad-Hussein, A. (2017). Genetic polymorphisms of human cytochrome P450 CYP1A1 in an Egyptian population and tobacco-induced lung cancer. *Genes and Environment*, 39, 7. <http://doi.org/10.1186/s41021-016-0066-4>
- Clinic-pathologic study of gastric and esophageal malignancies at the National Cancer Institute, Cairo University, Egypt, 2008–2012, February 2017, *European Journal of Cancer* 72(1):S80, DOI:10.1016/S0959-8049(17)30340-4, M. Aslan, Ahmed El Bastawisy
- Ahmed El Bastawisy, R Shehab, Abeer a Bahnassy, N Sabri, 160PBAP1 in advanced sporadic malignant pleural mesothelioma. *Annals of Oncology* 28(suppl_2) · April 2017 DOI: 10.1093/annonc/mdx093.001
- Bogan D, Meile L, El Bastawisy A, et al. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion. *BMC Cancer*. 2017;17:329. doi:10.1186/s12885-017-3283-8.
- A. El Bastawisy, R. Shehab, A. Bahnassy, N. Sabri, 160P BAP1 in advanced sporadic malignant pleural mesothelioma, *Annals of Oncology*, Volume 28, Issue suppl_2, April 2017,

mdx093.001, <https://doi.org/10.1093/annonc/mdx093.001>

- El Bastawisy, A., Yahia, M., Rahouma, M., Aboelazm, O. and Ahmed, J. (2017) Malignant Pleural Mesothelioma in Young People. *Journal of Cancer Therapy*, 8, 443-451.
<https://doi.org/10.4236/jct.2017.85038>
- BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival. Bahnasy AA1, El-Din RS2, Sabri NA3, Abdel-Rahman CA4, Bastawisy AE5. *Cancer Genet.* 2018 Dec;228-229:83-92. doi: 10.1016/j.cancergen.2018.10.001. Epub 2018 Oct 8.
- Nada Ezzeldin, Hebatallah Farouk, Dina M. Kandil, Amira Darwish, Ahmed El-Bastawisy, Impact of cell death pathway genes Fas 21377AA and FasL 2844CC polymorphisms on the risk of developing non-small cell lung cancer, *Egyptian Journal of Medical Human Genetics*, Volume 19, Issue 3, 2018, Pages 179-183, ISSN 1110-8630,
<https://doi.org/10.1016/j.ejmhg.2017.11.003>.
(<http://www.sciencedirect.com/science/article/pii/S1110863017301155>)
- Raghda Shehab El-Din*, Nagwa Ali Sabri, Abeer A Bahnasy, Ahmed El Bastawisy, The effect of BAP1 gene mutations on platinum-induced Double-strand

breaks (DSBs) in Egyptian patients with malignant Pleural mesothelioma (MPM), International Journal of Applied Research and Studies (IJARS) ISSN: 2278-9480 Volume VII, Issue 5 (May–2018)
www.ijars.ijarsgroup.com Manuscript.

- Ezzeldin, N., El-Lebedy, D., Darwish, A., El Bastawisy, A., Abd Elaziz, S. H., Hassan, M. M., & Saad-Hussein, A. (2018). Association of genetic polymorphisms CYP2A6*2 rs1801272 and CYP2A6*9 rs28399433 with tobacco-induced lung Cancer: case-control study in an Egyptian population. *BMC cancer*, 18(1), 525. doi:10.1186/s12885-018-4342-5.
- Mohamed, O., El Bastawisy, A., Allahlobi, N. *et al.* The role of CD68+ macrophage in classical Hodgkin lymphoma patients from Egypt. *Diagn Pathol* **15**, 10 (2020). <https://doi.org/10.1186/s13000-019-0912-3>.
- Schairer C, Hablas A, Eldein IAS, Gaafar R, Rais H, Mezlini A, Ayed FB, Ayoub WB, Benider A, Tahri A, Khouchani M, Aboulazm D, Karkouri M, Eissa S, Bastawisy AE, Yehia M, Gadalla SM, Swain SM, Merajver SD, Brown LM, Pfeiffer RM, Soliman AS. Risk factors for inflammatory and non-inflammatory breast cancer in North Africa. *Breast Cancer Res Treat.* 2020 Sep 2. doi: 10.1007/s10549-020-05864-3. Epub ahead of print. PMID: 32876910.

- Lu YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, Yap YS, Im SA, Rihani J, Gokmen E, El Bastawisy A, Karadurmus N, Lim YN, Lim CS, Duc LT, Chung WP, Babu KG, Penkov K, Bowles J, Alfaro TD, Wu J, Gao M, Slimane K, El Saghir NS. Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2-advanced breast cancer. *J Clin Oncol.* 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144. Epub ahead of print. PMID: 38771995.
- Enas A. El-Shorbagy, Noha A. El-Bassiouny, Amira B. Kassem, Ahmad Salahuddin, Mahmoud Mohamed Kamel, Ahmed El Bastawisy & Nermeen Nabeel Abuelsoud (11 Apr 2025): The impact of CBR3 (rs1056892) and ABCC1 (rs45511401) genetic polymorphisms on doxorubicin-induced cardiotoxicity and the potential role of brain natriuretic peptide as an early cardiac biomarker in breast cancer patients, *Expert Opinion on Drug Metabolism & Toxicology*, DOI: 10.1080/17425255.2025.2490736
- Kassem, A.B., Ahmed, A.A., El-Bassiouny, N.A. et al. EPHA5 and SOD2 genetic variants and their link to neurofilament light chain: early detection of taxane-induced neurotoxicity in Egyptian breast cancer patients. *Futur J Pharm Sci* 11, 78 (2025). <https://doi.org/10.1186/s43094-025-00827-1>

VI- Clinical trials:

- **Co-investigator:** Campto in small cell lung cancer protocol number: XRP4174D-3001.from 2006 till 2009.
- **Co-investigator:** Inflammatory Breast Cancer,A collaborative Project between NCI, Cairo and University of Michigan. USA from 2009-2014.
- **Co-investigator** Palliative Treatment of Malignant Pleural Effusion Using Bleomycin or Mistletoe preparation (Viscum Fraxini 2), a Prospective Randomized Controlled Trial, Study number: ME03.from February 2006till 2009.
- **Co-investigator:**A,Randomized,Multicenter Phase III Study Comparing the Combination of Pazopanib and Lapatinib Monotherapy in

patients with ErbB2 over expressing Inflammatory Breast Cancer. from 2008 till 2010.

- **Co-investigator:** Protocol H3E-EZ-S1 Randomized Phase 2 Study Comparing Pemetrexed plus Best Supportive Care with Best Supportive Care as Maintenance, Following First-Line Treatment with Pemetrexed-Cisplatin, in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer, from 2008 till 2010.

- **Co-investigator:** A phase III ,Randomized,Double-Blind,Placebo-Controlled trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat,MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy.From 2010 till 2011.

- **Co-investigator:** A phase III , randomized, double –blind placebo- controlled multicentre study of ASA404 in combination with Docetaxel in second –line treatment of patients with locally advanced or metastatic

(stage IIIb/IV) non-small cell lung cancer. From 2010 till 2011.

- **Co-investigator:** NGR015 study :Randomized double-blind phase III study of NGR-hTNF plus best investigator's choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM) (IPR/22), from 2011-2015.

- **Co-investigator:** A prospective double-blind randomized Phase III study of 300 mg versus 150 erlotinib in current smokers with locally advanced or metastatic NSCLC in second-line setting after failure on chemotherapy (CURRENTS), 2013.

- **Co-investigator :** An open label, single-arm phase IV study to assess the efficacy and safety of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring an EGFR mutation (Del19 or L858R) who have failed first-line treatment with platinum-based chemotherapy from 2014, ongoing.

- **Co-investigator** :Genetic Polymorphisms of the Human Cytochromes P450; CYP1A1 and CYP2A6 Genes in an Egyptian Population and Tobacco-Induced Lung Cancer. : An STDF project from 2014-ongoing.
- **Co-investigator** : An open label extension (Roll over) study of Vemurafenib in patients with BRAF v600 mutation positive malignancies previously enrolled in an antecedent Vemurafenib protocol: from 2015 ongoing.
- **Co-investigator:** THE PATTERN OF EGFR, K-RAS AND ALK MUTATIONS IN MIDDLE EASTERN PATIENTS WITH LUNG CANCER FROM EGYPT: collaborative project between the University of Cincinnati, USA and NCI, Cairo University from 2015-ongoing.
- **Primary clinical -investigator:** Frequencies and pattern of PDL-1and Ros genes aberrations in relation to genetic changes and outcome in NSCLC patients from Egypt: impact on response to treatment and survival outcomes, NCI, Cairo University from 2020-ongoing.
- **Principal Investigator:** COMPLEMENT-1: closed An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-)

Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for advanced disease. Novartis. Closed.

- **Principal Investigator:** RIGHT CHOICEA Phase II Randomized Study of the Combination of Ribociclib Plus Goserelin Acetate With Hormonal Therapy Versus Physician Choice Chemotherapy in Premenopausal or Perimenopausal Patients With Hormone Receptor-positive/ HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer. Novartis. From 2018, Ongoing

- **Principal Investigator:** ALEXANDRIA study: A Prospective Non-Interventional Study To Explore the Real-Life Management Of Postmenopausal women With Hormone Receptor- Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced/ Metastatic Breast Cancer In Egypt. Astrazeneca. From 2018, Ongoing.

- **Principal Investigator: TOBER study:** A DISEASE REGISTRY STUDY TO PROSPECTIVELY OBSERVE TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH HER2-POSITIVE UNRESECTABLE LOCALLY ADVANCED OR METASTATIC BREAST CANCER, Hoffman la Roche. 2020, ongoing.

- **Principal Investigator: KATE 3:** A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBOCONTROLLED PHASE III STUDY OF THE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE IN COMBINATION WITH ATEZOLIZUMAB OR PLACEBO IN PATIENTS WITH HER2-POSITIVE AND PD-L1 POSITIVE LOCALLY ADVANCED OR

METASTATIC BREAST CANCER WHO HAVE RECEIVED PRIOR TRASTUZUMAB- (+/- PERTUZUMAB) AND TAXANE-BASED THERAPY. Hoffman la Roche.2021, discontinued.

- **Principal Investigator:** HRDx-Ovarian: A Cross-sectional, Noninterventional, Multicentre Study to Determine the Prevalence of Homologous Recombination Deficiency Among Women With Newly Diagnosed, High-grade, Serous or Endometrioid Ovarian, Primary Peritoneal, and/or Fallopian Tube Cancer,Ongoing
- **Principal Investigator :** Study CJDQ443B12301 - KontRASt-02: “A randomized, controlled, open label, phase III study evaluating the efficacy and safety of JDQ443 versus docetaxel in previously treated subjects with locally advanced or metastatic KRAS G12C mutant non-small cell lung cancer”: 2023,ongoing.
- **Principal Investigator:** Clinical characteristics, treatment patterns, and survival outcomes for metastatic non–small cell lung cancer in patients treated with chemotherapy: A nationwide retrospective, real-world evidence, multicenter observational study in Egypt, 2022-2024.
- **Principal Investigator :** Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda® (Pembrolizumab) in Subjects with Advanced or

Metastatic Non-squamous Non-Small Cell Lung Cancer, 2025, ongoing.

- **Primary clinical investigator** :Assessment the relation between vitamin D levels and some mitogens expression in Non-Small Cell Lung Cancer, Postgraduate research project at NCI, Cairo University, 2025, ongoing.
- **Primary clinical investigator** : Evaluating the association of vitamin D with the expression levels of matrix metalloproteinase 2 and 9 in Non-Small cell lung cancer. Postgraduate research project at NCI, Cairo University, 2025, ongoing.

Supervision and discussion of MD and MSc Theses

- **Supervisor:** Molecular markers in advanced non-small cell lung cancer patients receiving Gemcitabine-Cisplatin chemotherapy MD thesis ,NCI, Cairo University from 2010-2015.
- **Supervisor:**Palliative chemotherapy versus palliative hypofractionated radiotherapy in advanced non-small cell lung cancer patients .MD thesis, NCI, Cairo University from 2010 ,ongoing.

- **Supervisor:** Diagnostic value of serum cytokeratin 19 fragment and tissue polypeptide antigen in Bronchogenic carcinoma. MD thesis Benha University. from 2010-2012.
- **Supervisor:** UGT1A1 Assessment in cancer patients receiving Irinotecan based chemotherapy. MSc thesis, faculty of pharmacy, Cairo University from 2010, on-going.
- **Supervisor:** Stem cell phenotype in inflammatory breast cancer. MSc thesis, NCI, Cairo University from 2011-2013.
- **Supervisor:** CD68 positive macrophages in classic Hodgkin lymphoma: thesis, NCI, Cairo University from 2012-2014.
- **Supervisor:** Clinicopathological differences between Right and Left side Colonic Cancer. MSc thesis, NCI, Cairo University from 2013-2014.
- **Supervisor/Discussant:** Frequency of BAP1 gene mutation in Egyptian patients with advanced sporadic malignant Pleural mesothelioma and it's Correlation with clinical outcome. MSc thesis, faculty of pharmacy, Ain shams University from 2013 to 2018.
- **Supervisor:** Clinicopathological study of Gastric and oesophageal malignancies at The National Cancer Institute (NCI) 5 years' experience. MSc thesis, NCI, Cairo University from 2013 to 2015.
- **Discussant:** Chemo-Raditherapy in head and neck cancer. MSc thesis, Faculty of Medicine, Ain shams University, 2015.
- **Supervisor/Discussant:** Clinical Impact of Src phosphorylation in advanced Non small cell lung cancer: MD thesis, NCI, Cairo University, Egypt and Cincinnati University, USA from August 2015-2025. Discussion on 11 June 2025.
- **Discussant:** Outcome of Patients with Borderline Ovarian Tumors: National Cancer Institute experience. MSc thesis, NCI, Cairo University,

June 2018.

- **Supervisor/ Discussant:** Outcome and prognostic features of patients with malignant pleural mesothelioma under combined modalities of therapy. Msc thesis, NCI, Cairo University, 2018-2019.
- **Supervisor/Discussant :** Prognostic value of Metformin in Locally Advanced Irresectable Non Small Cell Lung Cancer Patients. Msc thesis, NCI, Cairo University, 2017-2019.
- **Supervisor/Discussant :** Prognostic role of neutrophil lymphocyte ratio in advanced ovarian cancer. Msc thesis, NCI, Cairo University, 2019-2022.
- **Discussant:** Effect of delay in initiation of adjuvant Trastuzumab and dose interruptions on overall treatment outcome in breast cancer patients, a retrospective study. MSc thesis, Faculty of Medicine, Ain shams University, November, 2020.
- **Discussant:** Impact of Neutrophils to Lymphocytes Ratio on Response to Neoadjuvant Chemotherapy in Solid tumors. Msc thesis, NCI, Cairo University, 26th October 2022.
- **Discussant: Clinical impact of expression of SOCS3 ON Prognosis of adult acutel lymphoblastic leukemia.** Msc thesis, Faculty of Medicine, Mansoura University, 11 November 2022.
- **Supervisor/Discussant :** Predictive and Prognostic role of Tumor Infiltrating Lymphocytes In advanced Non Small Cell Lung Cancer. MD thesis, NCI, Cairo University, from 2019 to 23 May 2023.
- **Supervior:** Studying the associations between some genetic polymorphisms and Doxorubicin induced cardiotoxicity in breast cancer Egyptian patients. Msc thesis, Faculty of Pharmacy, Damanshour University. November 2021-2025.

- **Supervisor:** Studying the associations between genetic variants and Taxanes-induced neurotoxicity in breast cancer Egyptian patients. Msc thesis, Faculty of Pharmacy, Damansara University. November 2021, ongoing.
- **Supervisor:** Clinical and pharmacoeconomic assessment of CDK4/6 inhibitors for treatment of breast cancer in Egypt. PHD thesis, Faculty of Pharmacy, Beni-Suef University. 2024, ongoing.
- **Supervisor:** Clinicopathological characteristics and treatment outcome of patients with small cell lung cancer: A five years retrospective cohort study (2019-2023). Msc thesis, NCI, Cairo University, 2024, Ongoing.
- **Discussant :** Prognostic significance of Programmed Cell Death Ligand (PDL1) and KI67 in Pleural Mesothelioma value of. MD thesis, NCI, Cairo University, 21 December 2024.
- **Supervisor :** Clinical value of PI3K alteration In advanced Non Small Cell Lung Cancer. MD thesis, NCI, Cairo University, from December 2024, ongoing.
- **Supervisor :** Impact of Immunohistochemistry Subtyping based on GATA3 and CK5/6 on the Outcome of Patients with Muscle-Invasive Bladder Cancer after Neoadjuvant Chemotherapy. MD thesis, NCI, Cairo University, from April 2025, ongoing.

VII- CONFERENCES and COURSES ATTENDED:**Scientific activity in international conferences:**

- **Abstract:** ESMO congress 2010.Milan, Italy.
- **Poster presentation:** P17, 2nd MMOF, Istanbul, Turkey 2011.
- **Oral presentation:** at 2nd NCCN-MENA conference, Doha, Jan.2012.
- **Poster presentation:** 5th Asian pacific lung conference, Hong Kong, China, Aug.2012. Tissue polypeptide antigen as marker for lung cancer.
- **Speaker:** Best of ASCO, Grand Nile Tower Hotel, Cairo, 20-21 Sep. 2012.
- **Abstract:** ASCO 2013, Abstract ID : e14678
- **Poster presentation:** ICACT, Paris, France, 5-7 Feb.2013. Diagnostic and prognostic value of serum Cytokeratin 19 fragment in advanced lung cancer
- **Speaker:** Lung cancer screening, postgraduate course of lung cancer,25/Feb.2013.Cairo.
- **Poster presentation and Travel grant:** St. Gallen Breast conference, Switzerland, March 2013.

- **Speaker:** colorectal and Liver cancer multidisciplinary forum, Intercontinental City stars Hotel, Cairo, 16 May 2013
- **Speaker:** Best of ASCO, Grand Nile Tower Hotel, Cairo, 23-24 December 2013.
- **Poster presentation:** ASCO world gastrointestinal cancers symposium, Jan.2014. San Francisco, USA.
- **Case presentation and Travel grant:** the ESMO-Christie Lung Cancer Course 2014, 12-14 February 2014 in Manchester, UK.
- **Poster presentation and travel grant:** IMPAKT and pre-IMPAKT training course 7-10 May, 2014.Brussels, Belgium.
- **Oral presentation and travel Award:** 12th Annual Meeting of Japanese Society of Medical Oncology (JSMO2014), Fukuoka, Japan. 17-19 July 2014.
- **Speaker:** Best of ASCO, Intercontinental City stars Hotel, Cairo, 11-12 September 2014.
- **Speaker:** Egyptian Society of Surgical Oncology Conference, Grand Nile Tower Hotel, Cairo, 12-13 February 2015.
- **Poster presentation:** 16th World Conference on Lung Cancer (WCLC), Denver, USA, September, 2015.
- **Speaker:** Best of ASCO, Grand Nile Tower Hotel, Cairo, 10-11 Sep 2015.
- **Speaker:** Bridging Gaps in Oncology, Intercontinental City stars Hotel, Cairo, and 28-30 October 2015.
- **Speaker:** Mesothelioma Lilly meeting, Grand Nile Tower Hotel, Cairo, December 2015.

- **Speaker:** Egypt Mesothelioma Summit, Grand Fairmont Heliopolis Hotel, Cairo, 18th February 2016.
- **Poster presentation:** 6th European Lung Cancer Conference (ELCC), 13-16 April 2016, Geneva, Switzerland.
- **Poster Presentation and travel award:** 13th International Conference of the International Mesothelioma Interest Group (iMig 2016), May 1 – 4, 2016 at the International Conference Centre in Birmingham, UK.
- **Poste presentation:** ECCO 2017: European Cancer Congress, 27-30 January 2017, Amsterdam, The Netherlands.
- **Poster presentation and travel award:** 7th European Lung Cancer Conference (ELCC), 5-8 May 2017, Geneva, Switzerland.
- **Chairperson/Panelist:** Arab African Internatinonal Cancer conference, (AAICC) Cairo, Egypt, 10-11 October, 2019 and 2020, 2021, 2022, 2023,2024.
- **Chairperson/Panelist:** 8th Annual International Conference of Clinical oncology dept. Assiut University, Luxor, Egypt, 2017.2022, 2023,2024.
- **Chairperson/Panelist:** Ain-shams clinical oncology annual conference, September 2022, 2023,2024.
- **Speaker/Chairperson/Panelist:**Oncothoracic international congress On-Tic, Cairo, 23-24 June 2022, 2023, 2024.
- **Speaker:** National Conference for youth Health (NCYH), Cairo, Egypt 19 April 2018.
- **Speaker/chairperson/Panelist:** BIRDS ALERT, Luxor, Egypt, 2017, 2018, 2019, 2020, 2021, 2022, 2023.2024.

- **Speaker/Panelist:** Baheya Breast Cancer Conference, 2017,2018, 2019, 2020, 2021, 2022, 2023, 2024.
- **Speaker/Chairperson:** Third Oncology-Military-Day (onco-Milit-day), hosted by Ariana’s Association for Multidisciplinary Oncology Training and Awareness (AFSOMA), in “Hotel de Paris” in Tunis, Tunisia on the14th of April 2018.
- **Speaker:** Best of ASCO, Cairo, 2016, 2017, 2018, 2019.
- **Speaker, Chairperson:** Best of ESMO, Cairo, 26-27 January 2023, 2024.
- **Speaker:** Bridging Gaps in Oncology, Intercontinental City stars Hotel, Cairo, 2016, 2017, 2018, 2019,2021, 2022, 2023,2024.
- **Speaker:** Breast Cancer Meeting, 26 April 2018, King Hussein Cancer Center, Amman, Jordan.
- **Speaker training:**Abemaciclib Speaker Bureau:advancing clinical communications. 24th-25th January 2020.Vienna,m Austria.
- **Chairperson:** AIAZHAR Oncology Confrence, Intercontinental City stars Hotel, Cairo, 13 DEC.,2021.& September 2022., 2023, 2024
- **Secretary General:** Annual NCI, Cairo University conference, Bridging Gaps in Oncology, Intercontinental City stars Hotel, Cairo, 2021.
- **Secretary General:** OnchoBroncho international conference, JW Marriott Hotel, Cairo, 2022. Speaker: 2023.
- **Chairperson:** ISCO , Cairo, 2022, 2023, 2024.
- **Speaker:**Menofia oncology conference, Tolip hotel, Cairo, September 2023.

- **Speaker/Chairperson/Panelist/Trainer/Consultant /Advisory board:** several pharma-sponsored local, regional and international scientific meetings.

Attendant:

- **Travel grant:** ESMO Signaling Pathways in cancer, Sitges, Spain 1-2 March 2013
- **Travel grant:** ESMO Symposium on Immuno-Oncology 2013: Advances in cancer immunotherapy; from vaccines to antibodies and cell therapies, Geneva, Switzerland, 15 - 16 November 2013.
- **Invited and travel grant:** ESMO clinical trials workshop, Al-Ahsa KSA, March, 2013.
- **Invited and travel grant:** EORTC lung cancer group meeting dedicated to cancer clinical research in London (UK) on 21-22 November 2013.
- First Malaysian Egyptian oncology conference, May 2010. Kuala Lumpur, Malaysia.
- PASS, June 2013. Prague, Czech Republic.
- Lilly oncology forums 2010, 2011, 2012, 2013, 2014 at Beirut, Dubai, Istanbul, Dubai.
- Practical Workshops on GCP Clinical Trials Principles and Practice for Investigators and Clinical Research Personnel in MENA". On the 13th and 14th of September 2014, Dubai, United Arab Emirates.

- ESMO congress 2014, Madrid, Spain.
- Pan Arab cancer congress and Lebanese society of medical oncology forum, March LSMO 2015. And LSMO 2017, Beirut, Lebanon.
- Neuroendocrine tumors (NET) Interactive Course, 15-16 October 2015, IEO, European Institute of Oncology, Milan, Italy.
- EGM Oncology Leaders Summit (OLS), 12-14 June, 2015. Saint Petersburg, Russia.
- MAP 2015 – Molecular Analysis for Personalised Therapy, Paris, France - 23 Oct - 24 Oct 2015
- ESMO World Congress on Gastrointestinal Cancer 2016, Barcelona, Spain - 29 Jun - 02 Jul 2016.
- European Hematology Association, June 09 - 12, 2016 Copenhagen, Denmark (EHA) 2016 Congress.
- San Antonio Breast Cancer Symposium (SABCS) 2016, December 06 - 10, 2016 San Antonio, Texas, USA.
- The 23rd Fresenius Kabi Advanced Nutrition Conference, FRANC 16, Oncology-Moving Forward Nutrition, Bad Homburg, Germany, 1-3 June 2016.
- **Invited and travel expenses:** European Organization for research and treatment of Cancer (EORTC) lung

- cancer group meeting, EGAM 2017, 14-15 March, 2017, Brussels, Belgium.
- Preceptorship: Renal Cell Carcinoma, CIOCC, Universidad CEU San Pablo. Facultad de Medicina. 6-7 July 2017, Madrid Spain.
 - ITMIG 2017, 8th International Thymic Malignancy Interest Group annual Meeting, September 21-23 2017, Torino, Italy.
 - Champalimaud Breast Cancer Masterclass, 11-12 October, 2017 at The Champalimaud Centre for the Unknown in Lisbon, Portugal.
 - EGM Breast Cancer Investigator Meeting, 3-4 February, 2018 Hong Kong.
 - Preceptorship: Breast Cancer, 2-3 August 2018 at National Cancer Centre Singapore.
 - Integrative Medicine Meeting (IMM): Innovation and Experience in Oncology, 17-20 September, Rosenfeld, Germany.
 - ESMO Breast Cancer, Berlin, Germany - 02 May - 04 May 2019.
 - European Hematology Association, (EHA) June 13 - 16, 2019 Amsterdam, the Netherlands.
 - Preceptorship at the Breast center and Dept. Of Gynecologic and Obstetrics and CCC, Munich University hospital, Munich, Germany, 7-9 September 2019.
 - ESMO annual congress: 2017, Madrid. 2018, Munich. 2019, Barcelona, 2020, 2021, 2022, 2023, 2024.

-
- TECENTRIQ external Launch meeting, 11-12 November 2019, Dublin, Ireland.
 - PRECEPTORSHIP PROGRAMME BREAST CANCER July 13rd to 14th 2024, IEO Multidisciplinary management, standards of care, therapeutic targets and future perspectives
 - The American Society of Clinical Oncology (ASCO) annual meeting, Chicago, IL, USA. 2015, 2016, 2018, 2019.
 - American Society of Hematology (ASH) Annual meeting 2017, Atlanta. 2018, San Diego. 2019, Orlando. USA.

VIII- FUNDING and ACADEMIC AWARD/S:

- Cairo University award for best MD theses for the year 2009-2010.
- Award for best oral presentations at 2nd NCCN-MENA conference, Doha, Jan.2012.
- Future Medical Authors (FMA) 2014 Honorable Mention.
- Cairo University Award for international scientific publishing, May 2015.
- Inclusion in **Who's Who in the World® 2016** (33rd Edition) as one of the world's foremost achievers in the field of oncology.
- **Travel grant:** ESMO clinical trials workshop, Al-Ahsa KSA, March, 2013.
- **Travel grant:** St. Gallen Breast conference, Switzerland, March 2013. Diagnostic and prognostic issues in inflammatory breast cancer, poster 275.
- **Travel grant:** ESMO Signalling Pathways in cancer, Sitges, Spain 1-2 March 2013
- **Travel grant:** Oral Session 64 (OS64) [Colorectal Cancer, Chemotherapy and Adverse Effect], 11th Annual Meeting of Japanese Society of Medical Oncology (JSMO2013), Sendai, Japan. August 2013.
- **Travel grant:** ESMO Symposium on Immunology 2013: Advances in cancer immunotherapy;

from vaccines to antibodies and cell therapies, Geneva, Switzerland, 15 - 16 November 2013.

- **Travel grant:** EORTC lung cancer group meeting dedicated to cancer clinical research in London (UK) on 21-22 November 2013.
- **Travel grant:** the ESMO-Christie Lung Cancer Course 2014, 12-14 February 2014 in Manchester, UK.
- **Travel grant:** IMPAKT and pre-IMPAKT training course 7-10 May, 2014.Brussels, Belgium.
- **Travel Award:** 12th Annual Meeting of Japanese Society of Medical Oncology (JSMO2014), Fukuoka, Japan. 17-19 July 2014.
- **Travel award:** 13th International Conference of the International Mesothelioma Interest Group (iMig 2016), May 1 – 4, 2016 at the International Conference Centre in Birmingham, UK.

IX- PROFESSIONAL MEMBERSHIPS:

- Member of European Society for Medical Oncology (ESMO).
- Member of American Society of Clinical Oncology (ASCO).

- Member of International Association for Study of Lung Cancer (IASLC).
- Member of European organization for research and treatment of cancer (EORTC).
- Member of International Thymic Malignancy Interest Group (ITMIG)
- Member of the International Mesothelioma Interest Group (IMIG)
- Member of AACR
- Member of the Egyptian Cancer society.
- Member of Arab Foundation of Evidence Based Medicine (AFEEM).
- Member and one of founders of Egyptian society of Respiratory Malignancies.
- Chairman of board of trustees and founder of Socialized Foundation for Oncology Patients Support, OncoSpecialized (SFOPS).